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Abstract 
Background: The widespread emergence of anti‑malarial drug resistance has necessitated the discovery of novel 
anti‑malarial drug candidates. In this study, chloroquine derivatives were evaluated for the improved anti‑malarial 
activity.
Results: Novel two derivatives (SKM13 and SKM14) were synthesized based on the chloroquine (CQ) template con‑
taining modified side chains such as α,β‑unsaturated amides and phenylmethyl group. The selective index indicated 
that SKM13 was 1.28‑fold more effective than CQ against the CQ‑resistant strain Plasmodium falciparum. An in vivo 
mouse study demonstrated that SKM13 (20 mg/kg) could completely inhibit Plasmodium berghei growth in blood 
and increased the survival rate from 40 to 100% at 12 days after infection. Haematological parameters [red blood cell 
(RBC) count, haemoglobin level, and haematocrit level] were observed as an indication of clinical malarial anaemia 
during an evaluation of the efficacy of SKM13 in a 4‑day suppression test. An in vivo study showed a decrease of 
greater than 70% in the number of RBC in P. berghei‑infected mice over 12 days, but the SKM13 (20 mg/kg)‑treated 
group showed no loss of RBC.
Conclusions: CQ derivatives with substituents such as α,β‑unsaturated amides and phenylmethyl group have 
enhanced anti‑malarial activity against the CQ‑resistant strain P. falciparum, and SKM13 is an excellent anti‑malarial 
drug candidate in mice model.
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Background
Malaria is a disease affecting humans, caused by a proto-
zoan parasite of the Plasmodium genus, with 107 coun-
tries and territories having areas at risk of transmission 
[1]. The World Health Organization (WHO) reported the 
occurrence of 214 million cases worldwide in 2015, and 
the death of 438,000 people, mostly children in the Afri-
can region [2].
Successful malaria control in the past decade was 
dependent on treatment with efficacious anti-malarial 
drugs [3]. Quinoline drugs such as chloroquine (CQ) and 
quinine were the cornerstone of malaria treatment [4]. 
Quinine was used as anti-malarial medication from the 
seventeenth century until the 1920s, when CQ, a more 
effective synthetic anti-malarial, became available [5]. 
However, the extensive use of CQ led to the develop-
ment of a chloroquine-resistant malaria parasite Plasmo-
dium falciparum in Southeast Asia, Oceania, and South 
America in the late 1950s and early 1960s [6]. This drug 
resistance inspired a significant effort throughout the 
twentieth century to identify new anti-malarial agents for 
the improvement of global public health. There is still a 
need to produce “novel” drugs with different properties, 
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Although the molecular basis of chloroquine action is 
yet to be properly elucidated, the mechanism has tradi-
tionally been considered to occur through interference 
in the haemozoin crystal formation of the Plasmodium 
species, leading to detoxification of the malaria parasite 
[8, 9]. Chloroquine-resistant P. falciparum survives by 
reduction of drug accumulation in the digestive vacuole. 
In addition to being effective as an anti-malarial medica-
tion, CQ has emerged as a prospective adjunct with anti-
viral effects [10, 11], antitumour activity [12], and as an 
effector of cell-death by altering lysosomal function [13].
More efficacious drugs are currently available [5]. 
For example, artemisinin has been reported as a potent 
anti-malarial drug, but the emergence of resistance has 
increased the failure rate of artemisinin-based combina-
tion therapy [14–16]. As resistance to existing drugs devel-
ops, new drugs need to be introduced; for P. falciparum, 
the use of a combination of several drugs with different 
modes of action is recommended to provide an adequate 
cure rate and delay the development of resistance.
Several novel drug candidates based on the CQ struc-
ture, with modifications of both the side chain and the 
quinoline ring, have been reported [17–19]. In a previous 
study, the Michael-acceptor role of the α,β-unsaturated 
amide, which mimics the functional group present in gal-
linamide A and many anti-malarial chalcones, was found 
to stabilize the thiolate covalent bond between calpain, 
a cysteine protease required for cell cycle progression in 
Plasmodium parasites [20], and the β carbon of the α,β-
unsaturated amide [21, 22].
In the present study, two novel derivatives were 
designed based on the CQ structural template with a 
modified side chain, such as α,β-unsaturated amides and 
phenylmethyl group. These two derivatives were evalu-
ated for anti-malarial activity in vitro and in vivo.
Methods
Reagents
Chloroquine and atovaquone were purchased from 
Sigma Aldrich (St. Louis, USA). SYTOX® Green nucleic 
acid stain was purchased from Life Technologies (Carls-
bad, USA). The CellTiter 96® AQueous One Solution rea-
gent was purchased from Promega (Madison, USA).
Synthesis of SKM13 and SKM14
SKM13 and SKM14 were synthesized using the follow-
ing scheme: (1) the coupling of 4,7-dichloroquinoline and 
phenylalanine [23]; (2) the formation of Weinreb amide 
[24]; (3) reduction to aldehyde [25]; (4) Horner–Wads-
worth–Emmons reaction with the amide phosphonate 
[26]. The chemical structures were confirmed by proton 
NMR.
In vitro culture of Plasmodium species
Plasmodium falciparum 3D7 (American Type Culture 
Collection, ATCC PRA-405D) and P. falciparum FCR3 
(American Type Culture Collection, ATCC® 30932) 
were purchased from the ATCC (Manassas, USA). The 
chloroquine-susceptible strain Plasmodium berghei 
NK65 (MRA-268) and the atovaquone-resistant strain 
P. berghei NAT (MRA-415) were purchased from Bei 
Resources (Manassas, USA). The P. falciparum strains 
3D7 and FCR3 were grown in human erythrocytes as 
previously described [27]. Briefly, parasites were main-
tained in continuous culture with 5% haematocrit of 
type O human red blood cells suspended in Roswell Park 
Memorial Institute (RPMI) 1640 medium supplemented 
with 24  mM NaHCO3, 25  mM HEPES, 0.8% hypoxan-
thine, 0.9% Albumax, and 25 μg/mL of gentamicin. The 
6-well plates were placed in an incubator (atmosphere: 
5% CO2, 5% O2, and 90% N2) at 37  °C and the medium 
was changed daily when the level of parasitaemia was at 
least 5%. The parasite density was determined by Giemsa 
staining of thin smears and expressed as a percent-
age of infected erythrocytes in a field of a total of 500 
erythrocytes.
In vitro anti‑malarial activity by FACS analysis
To assess the effect of the compounds on malarial para-
site growth, the parasites were seeded in 48-well plates at 
a density of 0.5 in 2% haematocrit. The CQ compounds 
were then serially diluted in medium and incubated 
with the parasites for 48 h without any medium change. 
Finally, 100 μL of the P. falciparum cultures were with-
drawn from each well of the 48-well plate and 1 μL of the 
blood pellet was mixed in 5 mM SYTOX green solution 
to obtain a final volume of 1.5 mL. The mixture was left 
to stand in the dark for 30 min at room temperature and 
the anti-malarial activity of the compounds was analysed 
by fluorescence-activated cell sorting (FACS) using a 
FACS Calibur flow cytometer (BD Biosciences, Franklin 
Lakes, USA).
In vitro cytotoxicity
The MDCK cells were purchased from the Korean Cell 
Line Bank. The cells were seeded in a 96-well plate in 
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and incubated 
with serially diluted CQ compounds for 48 h.
After the incubation period, 20  μL of CellTiter 96® 
AQueous One Solution reagent was added to each well. 
After incubation for 1 h at 37 °C in a humidified 5% CO2 
atmosphere, the absorbance was measured at 490  nm 
using an enzyme-linked immunosorbent assay (ELISA) 
plate reader.
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Test for suppressive activity (Peter’s 4‑day test)
ICR female mice (Orient Bio Co., Seongnam, South 
Korea), 7  weeks old, were housed at Wonkwang Uni-
versity. All mice were bred and maintained under con-
stant conditions. Animal experiments were performed 
using an experimental protocol approved by the Ani-
mal Care and Use Committee at Wonkwang University 
(WKU16-40).
The atovaquone-resistant strain P. berghei NAT and the 
chloroquine-sensitive strain P. berghei NK65 were used 
to set up an infected mouse model. The parasites kept 
in liquid nitrogen were thawed at 37  °C and maintained 
by the serial passage of blood from mouse to mouse. In 
this study, each mouse was injected with 107 P. berghei-
infected erythrocytes/100  μL by intraperitoneal (i.p.) 
injection. At one day post-infection (dpi), drug treatment 
with SKM13 (20  mg/kg) was commenced. Atovaquone 
(4  mg/kg) and chloroquine (10  mg/kg) were intrave-
nously (i.v.) administered once a day for four consecu-
tive days as the control drug. Each day, tail blood was 
collected for FACS assessment of parasitaemia. Mouse 
weight and survival was checked every day, and haema-
tology assays were conducted at days 3, 6, 9, and 12 dpi.
Haematological assay
The haematological testing was conducted using a fully 
automated blood cell counter LC-660 (HORIBA Medical, 
Seoul, South Korea). The parameters evaluated included 
white blood cell count, red blood cell count, haemoglo-
bin, and haematocrit.
Statistical analysis
Results were statistically analysed using GraphPad Prism 
software 5.0. The experiments were compared using one-
way ANOVA followed by Bonferroni’s multiple com-
parison test. All results are expressed as mean  ±  SD 
(standard deviation of the mean). P values of less than 
0.05 were considered statistically significant.
Results
Characterization of SKM13 and SKM14
Two novel CQ derivatives (SKM13 and SKM14) were 
synthesized in this study (Fig. 1). CQ and two CQ deriva-
tives have two differences of chemical structure. In the 
structure of CQ, there is a small methyl group on the 
side chain [28] but two CQ derivatives have phenylme-
thyl group derived from phenylalanine at the same posi-
tion. Besides, both CQ derivatives have α,β-unsaturated 
amide instead of methyl group of CQ. A little difference 
of chemical structure between SKM13 and SKM14 indi-
cates that the α,β-unsaturated amide in SKM13 is shorter 
than that in SKM14.
In vitro anti‑malarial activity
After 48-h exposure to drugs, the standard in  vitro 
assays for anti-parasitic effects were determined by 
FACS analysis. It showed that SKM13 and SKM14 
had higher IC50 values than CQ; IC50 values of 
0.014  ±  0.002 (mean  ±  SD) μM, 0.17  ±  0.01  and 
0.23 ±  0.01  μM for CQ, SKM13, and SKM14, respec-
tively, against CQ-susceptible P. falciparum (3D7) 
(Table  1), In MDCK cells, the CC50 value indicated 
that SKM13 and SKM14 were more cytotoxic than 
CQ. Finally, it turned out that SKM13 and SKM14 had 
much lower selective index (SI) value (CC50/IC50) than 
that CQ. In contrast, the IC50 values for CQ-resistant 
P. falciparum (FCR3) confirmed the higher efficacy of 
SKM13 than CQ: CQ, SKM13, and SKM14 had IC50 
values of 0.62  ±  0.04 (mean  ±  SD) μM, 0.37  ±  0.01 
and 0.59 ±  0.02  μM, respectively. Therefore, the IC50 
values of SKM13 and SKM14 were 0.6- and 0.84-fold 
lower than that of CQ against CQ-resistant P. falcipa-
rum (FCR3), indicating that CQ derivatives were more 
effective than CQ as anti-malarial. Finally, the SI val-
ues showed that SKM13 was 1.28-fold more effective 
than CQ against CQ-resistant P. falciparum. In con-






















SKM13, R1 = H, R2 = N,N-dimethylaminoethyl
SKM14, R1 = CH3, R2 = N,N-dimethylaminopropyl
a) for SKM13
b) for SKM14
Fig. 1 Synthesis of SKM13 and SKM14. Reaction conditions: i l‑phenylalanine, phenol, 140 °C, 1 h, 55%. ii N,O‑dimethylhydroxylamine·HCl, 
EDAC·HCl, DMAP, TEA, DCM, rt, overnight, 72%. iii DIBAL, −40 °C, DCM, 5 h, 95%. iv phosphonate, DCM, KtOBu, 0 °C; (a) for SKM13 (71%), diethyl 
(2‑((2‑(dimethylamino)ethyl)(methyl)amino)‑2‑oxoethyl)phosphonate; (b) for SKM14 (70%), diethyl (2‑((3‑(dimethylamino)propyl)amino)‑2‑oxoe‑
thyl)phosphonate
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FACS analysis results can be found in the Additional 
file 1: Figures S1–S6).
Evaluation of the suppressive activity of SKM13 (Peter’s 
4‑day test)
The anti-malarial activity of SKM13 in a rodent model 
was assessed by a 4-day suppression test of 20  mg/kg 
of SKM13 in mice. As seen in Fig.  2, CQ-susceptible P. 
berghei NK65 parasites (107/mouse) were i.p. injected 
into ICR mice. After one day, SKM13 (20 mg/kg, in doses 
of 10 mg/kg, twice daily) and CQ (10 mg/kg, once daily) 
were i.v. administered for four consecutive days.
In the parasite-infected mice, a rise in parasitaemia was 
observed at 2 dpi, which decreased until 7 dpi. After 8 
dpi, parasitaemia increased exponentially and high para-
sitaemia (about 30%) was observed until 12 dpi (Fig. 2b). 
Parasitaemia in the SKM13-treated group (Fig.  2c) was 
significantly suppressed compared to that reported 
for the parasite-infected group (P  <  0.05), and the CQ-
treated group (Fig. 2d) showed no parasitaemia.
Body weight decreased in the parasite-infected mice. 
Normal body weight (27.09 ±  1.01  g, mean ±  SD) sig-
nificantly decreased (25.58 ± 0.93 g) at 2 dpi (P < 0.01), 
but remained unchanged in the SKM13-treated group 
(26.96  ±  0.56  g) at 12 dpi, demonstrating that SKM13 
(20  mg/kg) was effective in the maintenance of normal 
mouse metabolism until 12 dpi. CQ (10  mg/kg) also 
maintained normal mouse body weight.
Analysis of survival rate showed that SKM13 was effec-
tive in treating P. berghei infection. The parasite-infected 
group showed 20% mortality at 7 dpi, 40% mortality at 
9 dpi, and 60% mortality at 12 dpi. SKM13 treatment 
resulted in 100% survival rate in mice at 12 dpi (Fig. 2e).
To assess the anti-malarial activity of SKM13 against 
drug-resistant P. berghei, atovaquone-resistant P. berghei 
NAT parasites (107/mouse) were i.p. injected into ICR 
mice. After 1 day, SKM13 (20 mg/kg, in doses of 10 mg/
kg, twice daily), atovaquone (4  mg/kg, once daily), and 
CQ (10 mg/kg, once daily), were separately i.v. adminis-
tered for 4 consecutive days.
At 3 dpi, parasitaemia increased in the parasite-infected 
group and reached a peak at 8 dpi. After 8 dpi, a plateau in 
the level of parasitaemia was observed until 12 dpi (Fig. 3b). 
Parasitaemia in the SKM13-treated group (Fig.  3c) and 
CQ-treated group (Fig.  3d) was significantly suppressed 
compared to that reported for the parasite group (P < 0.05), 
which showed no parasitaemia. As anticipated, atovaquone 
(4  mg/kg) was unable to suppress the parasitaemia of 
atovaquone-resistant P. berghei NAT (Fig. 3e).
The normal body weight significantly decreased 
(P < 0.01) at 6 dpi but remained unchanged until 12 dpi 
in the SKM13-treated group. CQ (10 mg/kg) maintained 
the body weight of the infected mice. In the atovaquone-
resistant P. berghei NAT-infected group, the mortality 
rate at 7 dpi was 20 and 60% at 12 dpi. In contrast, the 
SKM13-treated group showed 100% survival rate until 12 
dpi (Fig. 3f ).
Effect of SKM13 on blood cell parameters
Changes in blood cell count are characteristic of Plasmo-
dium infection and haematological changes during the 
course of a malaria infection, such as anaemia, throm-
bocytopaenia, leukocytosis, or leucopenia, are well rec-
ognized [29]. In this study, WBC counts (mean  ±  SD) 
in normal ICR mice were 8.86  ±  1.86 (103/μL), which 
were in agreement with that reported previously [30]. 
Both P. berghei NK65 and NAT strains significantly 
increased WBC counts (P < 0.05) at 6 dpi and progres-
sively increased WBC counts were observed until 12 dpi 
(P < 0.001). In contrast, SKM13 or CQ treatment did not 
affect WBC counts (Fig. 4a). In addition to WBC counts, 
several other factors were observed as major indica-
tors of clinical malaria anaemia in the efficacy evalua-
tion of SKM13. Both P. berghei NK65 and NAT strains 
showed a large decrease in these values, with greater 
than 70% reduction in the main haematological param-
eters (RBC, haemoglobin, and haematocrit) for 12 days. 
However, SKM13 treatment in the 4-day suppression test 
did not alter the three parameters involved in anaemia 
(P < 0.001) (Fig. 4b–d).
Table 1 In vitro anti-malarial activity
Effects of chloroquine derivatives on the proliferation of CQ-susceptible and resistant strains of P. falciparum
Chloroquine-susceptible (3D7) and -resistant (FCR3) P. falciparum strains were cultured in the presence of increasing concentrations of CQ or each of the CQ 
derivatives. The values shown are the mean ± standard deviation (SD) from three independent experiments performed in triplicate
Strain Compound (IC50, μM) Relative IC50 (CC50, μM) Selective index(SI) (CC50/IC50) Relative SI
3D7 Chloroquine 0.014 ± 0.002 1.00 121.90 ± 8.51 8707.10 1.00
SKM13 0.17 ± 0.01 12.14 93.11 ± 5.56 547.70 0.06
SKM14 0.23 ± 0.01 16.42 47.06 ± 3.21 204.16 0.02
FCR3 Chloroquine 0.62 ± 0.04 1.00 121.90 ± 8.51 196.60 1.00
SKM13 0.37 ± 0.01 0.60 93.11 ± 5.36 251.70 1.28
SKM14  0.52 ± 0.02 0.84 47.06 ± 3.21 90.50 0.46
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Discussion
The present study demonstrated that hybrid molecules 
with a CQ structural template, including a quinolone 
moiety and a modified side chain such as the α,β-
unsaturated amides, could be a useful strategy in the 
development of anti-malarial drugs.
Because malarial disease is exacerbated by the emer-
gence of drug resistance to efficient treatments, novel 
anti-malarial medicines are an essential component of 
malaria control; a continuous search for different drugs 
with novel chemical structures and mechanism of actions 
is necessary [31]. As a new strategy in drug design, the 
hybrid molecule has been characterized by the rational 
approach of anti-malarial drug design and considered as 
a method to optimize the therapy with available drugs 
[32].
One type of these hybrid molecules, quinoline-novel tar-
get based hybrid molecules, is widely indicated, because 
the quinoline entity can inhibit β-haematin forma-
tion and contribute to a remarkable drug concentration 
within the digestive vacuole of Plasmodium [33]. So far, a 
quinoline-based isatin derivative, with the quinoline and 
isatin groups able to inhibit cysteine proteases, has been 
reported to show in  vitro anti-plasmodial activity [34]. 
However, the in vivo anti-plasmodial activity of the quino-
line-based isatin derivative has not yet been elucidated.
In this study, previous finding that the Michael-accep-




































































































































Fig. 2 Curative effect of SKM13 against chloroquine‑susceptible strain P. berghei in a 4‑day suppression test. Plasmodium berghei (NK65) parasites 
(107/mouse) were injected via the intraperitoneal (i.p.) route in mice (n = 7). After 1 day, drugs were administered via mouse vein for four consecu‑
tive days. After drug treatment, parasitaemia and weight were measured every day (a normal group, b P. berghei‑infected group, c SKM13‑treated 
group, d CQ‑treated group; green circle, parasitaemia; open circle, body weight) (**P < 0.01, ***P < 0.001). The values shown are the mean ± SD. The 
survival rate (% of control) is shown in (e)
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bond between the thiolate in a cysteine protease and the 
β carbon of the α,β-unsaturated amide [22] was com-
bined with quinoline as a multi-therapeutic strategy, 
leading to novel CQ derivatives (SKM13 and SKM14). 
CQ has a small methyl group on the side chain but 
SKM13 has a phenylmethyl group derived from pheny-
lalanine. In our result, SKM13 with a bigger substitu-
ent than methyl group in CQ showed better inhibitory 
activity, implicating that it may be preferable to develop 
derivatives with various larger substituents. Despite 
the structural similarities of the phenylalanine deriva-
tives SKM13 and SKM14, the selective index of SKM13 
was two-fold higher than SKM14. The α,β-unsaturated 
amide in SKM13 is shorter than that in SKM14. From the 
results, two effects of the structure of the derivative on 
the activity of the drug were estimated. First, although 
the alanine derivative is a similar size to chloroquine, the 
much larger phenyl group appeared to offer better bind-
ing to the target protein. Therefore, the possibility for the 
use of an amino acid with a larger residue than alanine 
could be the better strategy for anti-malarial design. Sec-
ond, as shown by the anti-malarial activity of the deriva-
tives with slightly different alkyl groups located at the 
nitrogen atom of the amide, the alkyl group could be 
tuned by size, bulkiness, and polarity.
SKM13 was identified as a potential anti-malarial drug 
by the complete clearance of parasitaemia, 100% survival 
rate, and unchanged haematological features in the 4-day 
suppression test. Specifically, SKM13 was a more effi-



























































































































































Fig. 3 Effect of SKM13 against chloroquine‑resistant strain P. berghei in a 4‑day suppression test. Plasmodium berghei (NAT) parasites (107/mouse) 
were injected via the i.p. route in mice (n = 7) and after 1 day, drugs were administered in the mouse vein for four consecutive days. After drug 
treatment, parasitaemia and weight were measured every day (a normal group, b P. berghei‑infected group, c SKM13‑treated group, d CQ‑treated 
group, e atovaquone‑treated group; red square, parasitaemia; white circle, body weight) (**P < 0.01, ***P < 0.001). The values shown are the 
mean ± SD. The survival rate (% of control) is shown in (f)
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α,β-unsaturated amides may be an important strategy for 
anti-malarial drug design.
 Haematological parameters, such as red blood cells, leu-
kocytes, and thrombocytes, are considered a biomarker of 
malarial infection and frequently monitored as an indica-
tor of drug efficacy against Plasmodium infection. Typi-
cally, WBC counts were significantly higher in patients 
with high parasitaemia than in those with low and moder-
ate parasitaemia [29]. Leukocyte counts, especially of neu-
trophils, have been reported significantly higher in patients 
with high parasitaemia compared to that in those with low 
parasitaemia, which supports the high WBC counts with 
high parasitaemia in the current rodent model.
Changes in RBC are the most typical feature of malar-
ial infections and the most common complication dur-
ing malarial infection is anaemia [35]. In the present 
study, more than 25% loss of total RBC, haemoglobin, 
and haematocrit demonstrated severe anaemia, and was 
observed at 6 dpi in both CQ-susceptible and P. berghei- 
(NK65)- and atovaquone-resistant P. berghei (NAT)- 
infected mice. The superior efficacy of SKM13 was sup-
ported by the absences of changes in the total RBC, 
haemoglobin, and haematocrit, which indicated 100% 
parasite clearance. Therefore, it is considered that SKM13 
is one of the compounds that can suppress the potential 
malarial burden.























































































































































































































Fig. 4 Effect of SKM13 on haematological parameters of P. berghei. The effect of SKM13 on haematological indices was examined every 3 days after 
treatment. At day 6, the WBC count of both of P. berghei NK65 and NAT strains significantly increased, and the other three parameters (red blood cell, 
haemoglobin, and haematocrit) decreased from 3 days after infection. Treatment of SKM13 (20 mg/kg) suppressed the changes of WBC, RBC, hae‑
moglobin, and haematocrit compared with the infected group from 1 to 12 days (*P < 0.05, ***P < 0.0001). The values shown are the mean ± SD
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Based on an in vitro study, SKM13 may not be as effec-
tive as CQ in CQ-susceptible P. falciparum, but may be a 
potentially attractive drug in CQ-resistant P. falciparum, 
which indicates that the mechanism of action may be dif-
ferent between CQ and SKM13.
The limitations of this study included the absence of 
in vivo results derived from CQ-resistant strain-infected 
mice. The study of CQ-resistant strain-infected mice will 
help the interpretation of the efficacy of SKM13. Future 
elucidation of the mode of action of SKM13 would be 
necessary for it to be considered as a novel strategy for 
anti-malarial drug design.
Conclusions
SKM13 with substituents such as phenylmethyl group and 
the α,β-unsaturated amides was more effective than CQ 
against the CQ-resistant strain P. falciparum. SKM13 treat-
ment (20 mg/kg) inhibited the P. berghei growth completely 
in the blood of mice and increased the mice survival rate 
from 40 to 100%. Haematological parameters supported the 
in vivo efficacy of SKM13 for 4-day suppression test. In con-
clusion, CQ derivatives with substituents such as the α,β-
unsaturated amides and phenylmethyl group can be a useful 
strategy for improving the anti-malarial activity and SKM13 
is an excellent candidate as anti-malarial drug.
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for IC50 of SKM14 in P. falciparum (FCR3).
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